Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 10519449
SERIAL NO

15422122

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs or cell penetrating asiRNAs) that inhibit ANGPT2 and/or PDGFB expression and are therefore useful for treating angiogenesis-associated diseases, such as cancer, AMD, and DME.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • OLIX PHARMACEUTICALS, INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Eom, Ji Seoul, KR 6 33
Hong, Sun Woo Seoul, KR 16 52
Lee, Dong Ki Seoul, KR 52 158
Lee, Hanna Seoul, KR 33 179
Lee, Sae-Lo-Oom Seoul, KR 3 1
Lee, Tae Yeon Seoul, KR 5 11
Yu, Dayeon Seoul, KR 4 8

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 30, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 30, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00